ESR1 and breast carcinoma: Triple‐negative breast cancer (TNBC) accounts for 15–20% of breast cancers, which is characterized as a subclass that estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor‐2 (HER‐2) deficient in the plasma membrane [1, 2].